Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levofloxacin
Drug ID BADD_D01275
Description Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin].[A190663] It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin[A190663] and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer).[L11638] Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.[A190663]
Indications and Usage For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.
Marketing Status Prescription; Discontinued
ATC Code J01MA12; S01AE05
DrugBank ID DB01137
KEGG ID D00588
MeSH ID D064704
PubChem ID 149096
TTD Drug ID D02RSN
NDC Product Code 68071-3093; 54288-140; 65862-538; 63415-0056; 68382-989; 17478-106; 70518-0932; 69097-282; 43063-457; 0143-9722; 61919-704; 80425-0076; 63187-384; 63323-355; 68083-415; 55111-279; 55150-156; 71335-0965; 67296-0897; 0904-6351; 70518-0968; 0781-5792; 67296-0972; 55154-5897; 42571-168; 51407-429; 50090-4572; 71335-0593; 63629-8070; 53002-3350; 68071-4512; 63187-514; 69097-289; 52343-120; 13668-083; 52343-121; 67296-1641; 55150-157; 0781-5791; 36000-295; 80425-0007; 68071-4926; 55111-281; 71205-234; 50090-1228; 65977-0039; 50090-2001; 67296-0975; 53002-2350; 55154-5898; 36000-294; 44567-436; 0143-9720; 44567-437; 63187-003; 68071-2074; 0143-9316; 68071-1860; 63187-833; 69097-287; 53002-2582; 53104-7550; 55111-280; 43063-637; 36000-048; 50383-286; 68071-4874; 68071-3166; 68180-241; 43063-459; 58118-1022; 68071-4726; 25021-132; 71335-0327; 71335-0133; 68071-4875; 67296-0977; 42708-122; 43063-638; 51407-430; 68180-242; 0527-1948; 0143-9721; 63187-925; 53069-0600; 68083-414; 71335-0391; 67296-1393; 50090-4797; 63187-004; 71335-0794; 68083-395; 50090-2498; 68071-3236; 71335-0434; 65841-692; 67296-1351; 71335-0380; 70934-094; 72578-098; 68071-4738; 43235-0007; 65841-691; 36000-296; 68071-3218; 63629-7681; 63187-438; 67296-0985; 31722-723; 65862-488; 65862-536; 54348-611; 50090-3214; 67296-1535; 72578-099; 0143-9317; 66721-200; 70518-2249; 61919-440; 43063-796; 53002-1350; 70934-050; 68788-6938; 0409-0528; 33342-023; 0781-5790; 67296-0744; 72578-100; 65841-693; 17478-107; 51407-428; 68083-416; 50090-4573; 49587-102; 68071-4900; 31722-722; 13668-084; 63629-4843; 61919-426; 65862-537; 70518-0453; 71205-002; 13668-082; 67296-1400; 68788-6816; 71335-0525; 80425-0009; 50090-4928; 70934-392; 67296-1546; 70771-1079; 52343-119; 45865-758; 36000-046; 44567-435; 55700-729; 0904-6353; 61919-987; 71335-1277; 31722-721; 68083-394; 68180-240; 67296-1325; 80425-0008; 72189-338; 36000-045; 67296-0998; 70518-2145; 71205-058; 72789-085; 80425-0077; 33342-022; 53002-1391; 0904-6352; 55525-0001; 36000-047; 71335-1208; 0143-9315; 33342-021
Synonyms Levofloxacin | Ofloxacin, (S)-Isomer | Levofloxacin Anhydrous | Anhydrous, Levofloxacin | Quixin | Levaquin
Chemical Information
Molecular Formula C18H20FN3O4
CAS Registry Number 100986-85-4
SMILES CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Atelectasis22.01.02.0010.000260%
Atrial fibrillation02.03.03.002--
Atrioventricular block02.03.01.002--Not Available
Attention deficit/hyperactivity disorder19.21.04.0010.000260%Not Available
Autoimmune hepatitis10.04.09.001; 09.01.07.0190.000520%Not Available
Autonomic nervous system imbalance24.06.01.005; 17.05.01.011; 08.01.01.0100.000433%Not Available
Back pain15.03.04.005--
Bacteraemia11.01.11.0010.000347%
Benign intracranial hypertension17.07.02.001--Not Available
Bilirubin conjugated increased13.03.01.0070.000520%Not Available
Bladder discomfort20.02.02.0190.000173%Not Available
Bladder irritation20.02.02.0200.000173%Not Available
Blindness17.17.01.003; 06.02.02.001--Not Available
Blindness unilateral17.17.01.016; 06.02.02.0090.000260%Not Available
Blister23.03.01.001; 12.01.06.0020.000953%Not Available
Blood albumin increased13.09.01.0020.000173%Not Available
Blood bilirubin increased13.03.01.008--
Blood creatinine increased13.13.01.0040.001387%
Blood glucose abnormal13.02.02.0080.001040%Not Available
Blood glucose decreased13.02.02.001--Not Available
Blood lactate dehydrogenase increased13.04.02.0020.000260%
Blood potassium decreased13.11.01.010--Not Available
Blood pressure abnormal13.14.03.001--Not Available
Blood pressure decreased13.14.03.002--Not Available
Blood pressure increased13.14.03.005--Not Available
Blood urea increased13.13.01.0060.000347%Not Available
Body temperature increased13.15.01.001--Not Available
Bone pain15.02.01.001--
Bradycardia02.03.02.002--Not Available
Bradypnoea22.02.01.0020.000347%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 30 Pages